Cerebropept (brain peptides)

2ml x 10 ampoules
5ml x 5 ampoules

Cerebropept contains low-molecular biologically active neuropeptides that penetrate the blood-brain barrier and directly reach nerve cells. The drug has an organ-specific multimodal effect on the brain, i.e. it provides metabolic regulation, neuroprotection, functional neuromodulation and neurotrophic activity.
a) metabolic regulation: Cerebropept increases the efficiency of aerobic energy metabolism of the brain, improves intracellular protein synthesis in the developing and aging brain.
b) neuroprotection: Cerebropept protects neurons from the damaging effects of lactic acidosis, prevents the formation of free radicals, increases survival and prevents the death of neurons under hypoxia and ischemia, reduces the damaging neurotoxic effects of excitatory amino acids (glutamate).
c) neurotrophic activity: Cerebropept is a nootropic peptidergic drug with proven neurotrophic activity similar to the action of natural neuronal growth factors (NGF), but manifested under conditions of peripheral administration.
d) functional neuromodulation: Cerebropept has a positive effect on cognitive impairment and memory processes.

- Alzheimer's disease;
- syndrome of cognitive impairment of various origins, including dementia;
- chronic cerebrovascular insufficiency (chronic cerebral ischemia, cerebrovascular insufficiency);
- ischemic stroke;
- traumatic brain injury;
- mental retardation in children;
- hyperactivity and attention deficit in children;
- in combination therapy - for endogenous depression resistant to antidepressants.

Per 1 ml contains:
Active ingredient: a complex of peptides isolated from the pig brain (Cerebrolysate-IV concentrate, liquid substance) 215.2 mg, which is equivalent to a total amino acid content of 140.0 to 210.6 mg.
Excipients: sodium hydroxide - 2.1 mg; water for injection - 792.7 mg.

Contraindications
- Individual intolerance to the drug;
- Severe renal failure;
- Epileptic status.
With caution:
The drug is used for allergic diathesis, diseases of an epileptic nature, including generalized epilepsy, due to a possible increase in the frequency of attacks.
Use during pregnancy and breastfeeding:
During pregnancy and breastfeeding, the drug should be used only after a thorough analysis of the ratio of the positive effect of treatment and the risk associated with its implementation. The results of experimental studies do not provide grounds to believe that the drug has any teratogenic effect or has a toxic effect on the fetus. However, similar clinical studies have not been conducted.